FDA Backs Reduced Monitoring for Patients on Travere’s Filspari

Travere Therapeutics says FDA approved a reduction in the frequency of liver function monitoring to every three months from monthly after the start of treatment with Filspari.

• Also removes the embryo-fetal toxicity monitoring requirement from the risk evaluation and monitoring strategy
• Filspari is the only Dual Endothelin Angiotensin Receptor Antagonist for the treatment of IgA nephropathy
• Shares rise 8.9% in postmarket trading

To view the source of this information click here

To contact the reporter on this story:
Marisa Coulton in Toronto at mcoulton1@bloomberg.net

To contact the editors responsible for this story:
Zachary Fleming at zfleming2@bloomberg.net

Marisa Coulton, Jim Silver ...